SCHEMBL7583545

SCHEMBL7583545

CNC(=O)[C@H](CC(C)C(N)=O)C[C@@H](O)[CH]CC1CCC(F)(F)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4067961 0.78 ALDH1A1 (0.34)
SCHEMBL4073024 0.75 EPHX1 (0.36)
SCHEMBL4066674 0.75 MMP1 (0.32)
SCHEMBL4063347 0.69 CCR1 (0.37)
SCHEMBL7583549 0.68 REN (0.41)
SCHEMBL4058890 0.68 CCR1 (0.36)
SCHEMBL4065205 0.67 FFAR2 (0.37)
SCHEMBL4069707 0.65 MMP3 (0.42)
SCHEMBL4063155 0.65 SMN1; SMN2 (0.40)
SCHEMBL4066009 0.64 REN (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020198207-A1 Novel Hexanoic acid derivatives KATH JOHN CHARLES (US) 2002-12-26 US disclosed
US-6403587-B1 AUTOIMMUNE DISEASES, ACUTE AND CHRONIC INFLAMMATORY CONDITIONS, ALLERGIC CONDITIONS, INFECTION ASSOCIATED WITH INFLAMMATION, VIRAL, TRANSPLANTATION TISSUE REJECTION, ATHEROSCLEROSIS, RESTENOSIS, HIV INFECTIVITY, AND PFIZER INC. 2002-06-11 US disclosed